Genotyping by amplicon melting is a minimalistic approach to genotyping, requiring only PCR, a fluorescent DNA dye, and single-color acquisition of a melting curve in a closed tube. Multiplex genotyping for the F5 1 [coagulation factor V (proaccelerin, labile factor)] Leiden (1691GϾA), F2 [coagulation factor II (thrombin)] 20210GϾA, and MTHFR [methylenetetrahydrofolate reductase (NAD(P)H)] 1298AϾC and 677CϾT thrombophilia mutations distinguishes up to 81 (3 4 ) combinations in solution without physical processing (1 ). Furthermore, we previously suggested that it might be possible to detect additional rare variants within the sequences of the quadruplex amplicons by a combination of melting temperature (T m ) and shape discrimination enabled by highresolution melting analysis. Amplified heterozygotes have a complex melting curve shape consisting of 2 homoduplexes (wild type and mutant) and 2 heteroduplexes that are influenced by the class of singlenucleotide polymorphism and other variants within the amplicon. These qualities yield unique melting curves for most heterozygotes (2 ).
Because we perform thousands of single-target genotyping assays annually on these thrombophilia mutations, some unexpected rare variants have been identified by abnormal dual hybridization probe melting (3 ). Archived, deidentified DNA samples (ARUP Laboratories protocol IRB #7275) with rare heterozygous variants confirmed by sequencing were analyzed by the quadruplex melting assay with a new instrument (LS-32; Idaho Technology) that both amplifies and melts 32 samples with a resolution similar to that of the original LightCycler/HR-1 method (4 ). For melting analysis, we used custom software to perform temperature correction and T m assignment (1, 4, 5 ) .
The rare thrombophilia variants included those between the primers of each amplicon (MTHFR variants 685AϾG, 679GϾA, and 1317CϾT; F5 variant 1690CϾT; and F2 variant 20209CϾT) , those under the primers (MTHFR variant 1293TϾC and F5 variant 1689GϾA) , and 1 sample with 2 rare variants [one between the primers and the other under a primer (MTHFR 1317CϾT/1331CϾT)]. Melting data, including T m s, ⌬T m s, the peak width at one-half the peak height, and the position of the variant within the amplicon, were collected for all of the variants for each of the 4 loci ( Table 1) .
The variants that were located between primers (1690CϾT, 1298AϾC/1317TϾC, 679GϾA, 685AϾG, and 20209CϾT) were easily detectable by either unique T m shifts and/or melting curve shapes that differed from the controls for each of the 4 loci. Variants located under the primers (1689GϾA and 1293TϾC) had melting profiles that matched the profile of the corresponding wildtype control. One sample (MTHFR 1298AϾC/1317CϾT/1331CϾT) with rare variants both between primers and under one of the primers had a unique melting pattern that also could be distinguished from other genotypes.
The ability of amplicon melting to discriminate rare variants located between the primers increases genotyping accuracy. Both T m and curve shape can be used to identify unexpected variants. Usually sequencing is used to confirm specific variants, but the possibility of identification by reference to a catalog of variant melting curves has not been fully explored. Another future possibility is in silico prediction of specific variants from the melting curve shape. Although our ability to identify variants by melting analysis will continue toimprove,variantsundertheprimers are likely to be missed, a problem common to many PCR methods. 
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Influence of Sample Storage Conditions on Sweat Chloride Results

To the Editor:
Sweat chloride samples may be collected in areas of a hospital that are removed from the chemistry laboratory, and a delay in analysis may compromise the integrity of the sample. Clinical and Laboratory Standards Institute (formerly NCCLS) (CLSI) document C34-A3 (1 ) recommends that sweat chloride samples collected on filter paper or gauze be promptly weighed and then refrigerated in the event that the sample cannot be analyzed immediately. The citation supporting the CLSI requirements (2 ) did not examine other storage conditions. We investigated the stability of simulated sweat samples stored under various conditions for 3 to 5 days.
KCl (Aldrich Chemical) was dissolved in 100 mL of deionized water to achieve simulated sweat with concentrations of 17, 27, 41, 63, and 85 mmol/L. Samples were then prepared by adding filter paper (Grade 541, 5.5 cm in diameter; Whatman) to snap cap vials (Fisher) that were preweighed wilth a Mettler AE240-S analytical balance. We pipetted 100 L of each concentration onto the filter paper and immediately capped the vials. The day 0 vials were reweighed immediately. The vials for the other storage conditions were weighed just before chloride measurement. At the time of analysis, we added 5.5 mL of Chloridometer Acid Reagent (Labconco) to each vial, weighed the vial, and incubated it for 40 min at 21°C-23°C. The filter paper was then removed and the remaining volume was assessed gravimetrically to correct for any volume removed with the filter paper. Coulometric titration was performed as described in the CLSI guideline with a Labconco Digital Chloridometer (Model 4425000). Sweat chloride was calculated in millimoles of chloride per liter of sweat.
Sweat samples analyzed immediately (day 0) were used as controls in evaluating the influence of storage. The remaining samples were incubated at either room temperature (21°C-23°C) or refrigerated temperature (2°C-8°C) for 72, 96, and 120 h before analysis (Table 1) . Increases in sweat chloride concentrations were highly variable, ranging from 20.9%-65.8% at room temperature and 2.9%-19.2% at refrigerated temperatures in vials stored for 3 to 5 days. These data support the conclusion that loss of water due to evaporation before weighing the vial plus the filter paper containing sweat caused unacceptable results. The chloride concentrations in the vials containing sweat plus acid diluent were nearly identical for each concentration, with a mean change of 0.6% (range, Ϫ1.6% to ϩ7.1%) for all concentrations, regardless of storage condition. These data support the conclusion that no loss of chloride occurred during vial storage.
When the sweat weight from day 0 controls was used to recalculate the sweat chloride concentrations for day 5 storage conditions, the percentage change for room temperature and refrigerated samples ranged from ϩ1.7% to ϩ6.1% at both conditions, with low concentrations showing the greatest change in percentage (Table 1 ). This finding suggests that the weight of the sweat sample must be measured immediately but that the chloride can be measured up to 5 days later. Sweat chloride concentrations can be measured reliably because the sweat sample (typically 75-150 L) is extracted into a relatively large volume of solution (5.5 mL) in the measurement vial. For example, we observed a worstcase loss of 32.7 mg from 101.1 mg of sweat, which represents a decrease in the measurement vial from 5601.1 mg to 5568.4 mg (Ϫ0.58%). This small change would negligibly influence the calculated sweat chloride concentration as long as the original weight of the sweat was known.
Methods to prevent evaporation were investigated by storing simulated sweat samples under 6 conditions: at room temperature, refrigerated, at room temperature with a Parafilm seal, refrigerated with a Parafilm seal, at room temperature in a sealed plastic specimen bag (12 in ϫ 15 in; VWR) and refrigerated in a sealed plastic specimen bag. Parafilm-sealed samples were prepared by wrapping a Parafilm strip (1 in ϫ 12 in) tightly around the cap and vial. Samples were weighed at initial preparation, at 72 h, and at 120 h. Table 1 shows that refrigerated, Parafilm-sealed samples had the least evaporation (1.1% at 3 days and 2.4% at 5 days), whereas room temperature samples had the most evaporation (19.1% at 3 days and 32.3% at 5 days).
We conclude that sweat samples should be delivered immedi-
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